This was a retrospective cohort study using the multicenter, nationwide LUNA registry in Japan. The population included 1134 patients with systemic lupus erythematosus (SLE) and a BMI ≥18.5 kg/m2. The study compared relapse rates between patients with obesity (BMI ≥25 kg/m2) or overweight (BMI ≥25 kg/m2 and <30 kg/m2) and those of normal weight (BMI 18.5 to <25 kg/m2).
The primary outcome was the one-year relapse rate after LUNA registration, defined as an increase in glucocorticoid dosage. In the main analysis, obesity was associated with a significantly reduced relapse rate (OR 0.52, 95% CI 0.30–0.90, p = 0.02). The absolute numbers were 909 patients in the normal weight group and 225 in the obese group.
In a sensitivity analysis, overweight was an independent factor associated with a reduced risk of SLE relapses (OR 0.43, 95% CI 0.22–0.82, p = 0.01). No safety data were reported.
Key limitations include the retrospective design, relapse definition based solely on glucocorticoid dosage increase, and potential for unmeasured confounding despite multivariate adjustment. The practice relevance suggests that appropriate weight management guidance may help prevent SLE relapses, but the association does not establish causation.
View Original Abstract ↓
Recent reports have suggested an association between the pathogenesis of systemic lupus erythematosus (SLE) and various adipokines secreted by adipocytes. However, the impact of obesity on the susceptibility to SLE relapses remains unclear. This study investigated the association between obesity and relapse in patients with SLE using a large, multicenter cohort.
Patients enrolled in LUNA, a nationwide, multicenter SLE registry in Japan, with a body mass index (BMI) ≥ 18.5 kg/m2 were included in the study. Participants were divided into two groups: the obese group (BMI ≥ 25 kg/m2) and the normal weight group (18.5 kg/m2 ≤ BMI < 25 kg/m2). The one-year relapse rate after LUNA registration was compared between the two groups. Relapses were defined as an increase in glucocorticoid dosage during follow-up. A multivariate analysis was performed using generalized linear models adjusted for age, sex, disease duration, education level, glycated hemoglobin level, disease activity (Systemic Lupus Erythematosus Disease Activity Index), organ damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), current prednisolone (PSL) dose, past maximum PSL dose, calcineurin inhibitor use, and incretin-related drug use as covariates. Furthermore, a sensitivity analysis was performed using the same statistical model and covariate adjustments to reclassify participants into the overweight (BMI ≥ 25 kg/m2 and < 30 kg/m2) and non-overweight (BMI ≥ 18.5 kg/m2 and < 25 kg/m2 or BMI ≥ 30 kg/m2) groups.
Among the 1, 134 patients, 909 were classified as normal weight and 225 as obese. The multivariate analysis showed that obesity significantly reduced relapse rates (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.30-0.90, p = 0.02). The sensitivity analysis revealed that overweight was an independent factor associated with a reduced risk of SLE relapses, with an OR lower than that for obesity in the primary analysis (OR 0.43, 95% CI 0.22–0.82, p = 0.01).
Patients with mild obesity had lower relapse rates than those with normal BMI. The findings suggest that metabolic status may influence the disease course of SLE. Appropriate weight management guidance, including avoiding excessive dietary restriction, may help prevent SLE relapses.